

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 June 2018 (28.06.2018)



(10) International Publication Number
WO 2018/115204 A1

(51) International Patent Classification:

C07K 7/08 (2006.01) A61K 51/08 (2006.01)
A61K 51/04 (2006.01) A61K 47/64 (2017.01)

(21) International Application Number:

PCT/EP2017/083954

(22) International Filing Date:

20 December 2017 (20.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1622142.6 23 December 2016 (23.12.2016) GB
1713560.9 23 August 2017 (23.08.2017) GB

(71) Applicant: BICYCLETX LIMITED [GB/GB]; Building
900, Babraham Research Campus, Cambridge CB22 3AT
(GB).

(72) Inventors: TEUFEL, Daniel; Meditrina Building, c/o Bi-
cycle Therapeutics Limited, Babraham Research Campus,
Cambridge Cambridgeshire CB22 3AT (GB). MUDD,
Gemma; Meditrina Building, c/o Bicycle Therapeutics
Limited, Babraham Research Campus, Cambridge Cam-
bridgeshire CB22 3AT (GB). PAVAN, Silvia; Meditri-
na Building, c/o Bicycle Therapeutics Limited, Babraham
Research Campus, Cambridge Cambridgeshire CB22 3AT
(GB).

(74) Agent: MASCHIO, Antonio; 30 Carlton Crescent,
Southampton Hampshire SO15 2EW (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PEPTIDE LIGANDS FOR BINDING TO MT1-MMP

(57) Abstract: A peptide ligand specific for MT1 -MMP comprising a polypeptide comprising two diaminopropionic acid (Dap) or N-alkyldiaminopropionic acid (N-AlkDap) residues, and a third residue selected from cysteine, Dap or N-AlkDap, separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap residues of the polypeptide and by covalent thioether linkages with the cysteine when the third residue is cysteine, such that two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence of formula (II): -A₁-X₁-U/O₂-X₃-X₄-G₅-A₂-E₆-D₇-F₈-Y₉-X₁₀-X₁₁-A₃- (SEQ ID NO: 1) (II) or a pharmaceutically acceptable salt thereof; wherein: A₁, A₂, and A₃ are independently cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3- diaminopropionic acid (N-AlkDap), or N-beta-haloalkyl-L-2,3-diaminopropionic acid (N- HalkDap), provided that at least one of A₁, A₂, and A₃ is Dap, N-AlkDap or N-HalkDap; X represents any amino acid residue; U represents a polar, uncharged amino acid residue selected from N, C, Q, M, S and T; and O represents a non-polar aliphatic amino acid residue selected from G, A, I, L, P and V.

WO 2018/115204 A1